These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22649139)

  • 1. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?
    Hartmann H; Müller J; Marschner N
    J Clin Oncol; 2012 Sep; 30(26):3317-8; author reply 3318. PubMed ID: 22649139
    [No Abstract]   [Full Text] [Related]  

  • 2. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
    Hurwitz HI; Lyman GH
    J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468
    [No Abstract]   [Full Text] [Related]  

  • 3. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 4. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab adds survival benefit in colorectal cancer.
    Susman E
    Lancet Oncol; 2005 Mar; 6(3):136. PubMed ID: 15759361
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer.
    Oncology (Williston Park); 2011 Nov; 25(12):1232. PubMed ID: 22229221
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
    Stein A; Petersen V; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Boxberger F; Leutgeb B; Hinke A; Kutscheidt A; Arnold D
    Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
    Giuliani J; Martelli S; Piacentini P; Bonetti A
    Tumori; 2015 Mar; 101(1):e32-3. PubMed ID: 25702648
    [No Abstract]   [Full Text] [Related]  

  • 10. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
    Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
    J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
    [No Abstract]   [Full Text] [Related]  

  • 11. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.
    Sarmiento R; Longo R; Gasparini G
    Int J Biol Markers; 2012 Dec; 27(4):e286-94. PubMed ID: 23280126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
    Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
    Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
    Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 16. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].
    Watanabe T; Nishiwaki N; Kajiwara Y; Okamoto T; Miyamoto M; Kohjima T; Watanabe Y; Yoshino K; Kawai T; Toda K; Nobuhisa T; Endo Y; Matsumoto Y; Watanabe N; Kai K; Sato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):71-4. PubMed ID: 23306921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Boisen MK; Johansen JS; Larsen O; Jensen BV
    Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
    Rossi L; Veltri E; Zullo A; Zoratto F; Colonna M; Di Seri M; Longo F; Mottolese M; Giannarelli D; Ruco L; Romiti A; Barucca V; Adua D; Tomao S
    Future Oncol; 2012 Sep; 8(9):1193-7. PubMed ID: 23030493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.